KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Receivables (2016 - 2025)

Historic Receivables for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $8.5 billion.

  • Amgen's Receivables rose 1603.12% to $8.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 billion, marking a year-over-year increase of 1603.12%. This contributed to the annual value of $7.3 billion for FY2024, which is 601.03% down from last year.
  • Latest data reveals that Amgen reported Receivables of $8.5 billion as of Q3 2025, which was up 1603.12% from $8.7 billion recorded in Q2 2025.
  • Over the past 5 years, Amgen's Receivables peaked at $8.7 billion during Q2 2025, and registered a low of $4.4 billion during Q1 2021.
  • In the last 5 years, Amgen's Receivables had a median value of $6.1 billion in 2023 and averaged $6.3 billion.
  • As far as peak fluctuations go, Amgen's Receivables crashed by 1653.0% in 2021, and later soared by 2548.31% in 2025.
  • Quarter analysis of 5 years shows Amgen's Receivables stood at $5.7 billion in 2021, then rose by 10.36% to $6.3 billion in 2022, then increased by 24.06% to $7.8 billion in 2023, then fell by 6.01% to $7.3 billion in 2024, then increased by 16.25% to $8.5 billion in 2025.
  • Its Receivables stands at $8.5 billion for Q3 2025, versus $8.7 billion for Q2 2025 and $8.1 billion for Q1 2025.